Jianfeng Group Pro 2015-007 (Jianfeng Group Daily Related Party Transaction Announcement)
Release time:
2020-08-05
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Pro 2015-007
Bond Abbreviations: 13 Peak 01 Bond Code: 122227
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Regular Related Party Transaction Announcement
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .
Basic Information of 1. Daily Related Party Transactions
Review Procedures for Implementation of (I) Daily Related Party Transactions
Jinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinhua Pharmaceutical Company") purchases drugs from related party Tianjin Tianshili Pharmaceutical Marketing Group Co., Ltd. (hereinafter referred to as "Tianshili Marketing Group"). It is estimated that the purchase amount in 2015 will be between 0.5 and 5% of the company's audited net assets at the end of 2014 (no more than 103.0351 million yuan). Therefore, this related party transaction needs to be submitted to the board of directors for deliberation, but does not need to be submitted to the general meeting of shareholders for deliberation.
On April 17, 2015, the company held the second meeting of the ninth board of directors. All nine directors of the company attended the meeting in person. The related directors Mr. Jiang Xiaomeng and Mr. Du Zihong avoided voting on the proposal, which complied with the relevant provisions of the "Company Law" and the "Articles of Association", and the resolutions made were legal and effective. After deliberation and voting, the board of directors deliberated and passed the daily related party transaction proposal with 7 votes in favor, 0 votes against and 0 abstention.
The independent directors of the company reviewed the matter in advance and agreed to submit the proposal to the second meeting of the ninth board of directors of the company for deliberation. The independent directors of the company expressed their independent opinions on the adoption of the proposal by the board of directors, and believed that the formation of the resolution complied with the "Company Law", the company's "Articles of Association" and other relevant provisions, and did not harm the interests of small and medium shareholders.
Forecast and Implementation of (II)'s Last Daily Related Party Transaction
The Company issued a public announcement on April 15, 2014. It is estimated that the amount of drugs purchased by Jinhua Pharmaceutical Company from Tianshili Marketing Group in 2014 will be between 0.5 and 5% (between 8.685 million yuan and 86.8499 million yuan) of the Company's audited net assets at the end of 2013. The actual amount incurred in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions, which did not exceed the expected range.
2. Related Party Introduction and Association Relationship
(I) the basic situation of related parties.
1. Jinhua Pharmaceutical Company: Established in January 1994, its domicile is located at 1180 Huancheng East Road, Jinhua City, its legal representative is Jin Xuecai, and its registered capital is 22 million yuan, of which: the company accounts for 10%, Zhejiang Jianfeng Pharmaceutical Co., Ltd., its holding subsidiary, accounts for 90%, and its main business is drug management. Wholesale and retail of prepackaged food; dangerous chemicals and medical devices; chemical reagents (except dangerous goods); glass and products; textiles, clothing and household daily necessities (except dangerous goods); fitness equipment supplies; computers, software and auxiliary equipment; wholesale and retail of teaching molds; exhibition services; medical information services; branches operate with valid certificates: purchase and processing of traditional Chinese medicine. The drug business license mainly includes: sales of proprietary Chinese medicines, Chinese medicinal materials, Chinese medicinal tablets, chemical preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, etc. The audited net profit for 2014 was 6.5056 million yuan, the net assets at the end of 2014 was 73.169 million yuan, and the liabilities were 237.9614 million yuan.
2, Tianshili Marketing Group: The company was established in 1999 February. The company's domicile is Tianshili Modern Chinese Medicine City, Xinyibai Avenue, Beichen Science and Technology Park, Tianjin, with its legal representative Yan Kaijing and registered capital of 25900 yuan, the business scope is the wholesale of Chinese herbal pieces, Chinese medicinal materials, Chinese patent medicines, chemical raw materials and their preparations, antibiotics, biochemical drugs, biological products, and diagnostic drugs; chemical raw materials ( except hazardous chemicals and precursor drugs ) , Wholesale and retail of cosmetics, daily chemical products, packaging materials and containers, plastic products, molds, and plastic raw materials; health food (hard capsules, soft capsules, granules, tablets, oral liquids, tea bags, health wine) wholesale and retail; disposable sterile syringes (needles), infusion sets (needles), corneal contact lenses and nursing solutions, medical polymer materials and products, physical therapy and rehabilitation equipment, medical hygiene materials and dressings, Chinese medicine equipment, general diagnosis equipment, Ward care equipment and appliances, household blood glucose meters and test strips, pregnancy diagnosis test strips, condoms wholesale; self-employed and agent of all kinds of goods and technology import and export business, but the state restricts the company to operate or prohibits the import and export of goods and technology, operating feed processing and "three to one supplement " business, operating trade and re-export trade, pre-packaged food wholesale and retail. The net profit attributable to the parent company in 2014 was 16,080.14 yuan, The net assets attributable to the parent company at the end of 2014 were 9,234.05 yuan, and the liabilities were 482,239.84 yuan.
The relationship between the (II) and the listed company
Because Tianshili Marketing Group is the holding subsidiary of Tianshili Pharmaceutical Group Co., Ltd., and Tianshili Pharmaceutical Group Co., Ltd. is the holding subsidiary of Tianshili Holding Group Co., Ltd. (hereinafter referred to as "Tianshili Group"), tasly Group is an associate of the Company and the Company has two directors who are also directors of Tasly Group, so Jinhua Pharmaceutical Company is related to Tasly Marketing Group.
(III) The amount of related party transactions in 2014 was 14.6314 million yuan, accounting for 2.13 percent of the amount of similar transactions. The implementation was good and there were no disputes.
Main Contents and Pricing Policy of 3. Related Party Transaction
Jinhua Pharmaceutical Company plans to continue to purchase drugs from Tianshili Marketing Group for sale this year. The main contents of this related party transaction are as follows:
(1) Transaction Target: Compound Danshen Dripping Pills, Yangxue Qingnao Granules, etc.
(2) Transaction Price: Agreement Price.
(3) settlement method: full payment according to the sales amount of last month.
(4) Agreement Validity Period: The validity period of the agreement signed by the above-mentioned related parties is 1 year from the date of signature by the legal representatives or authorized representatives of both parties.
(5) Other matters: If there is a major change in the content of this related party transaction during the implementation of the agreement, the company will disclose it in accordance with relevant regulations, and investors are requested to pay attention.
Purpose of 4. Related Party Transaction and Impact on Listed Companies
This related party transaction is to use Jinhua Pharmaceutical Company's existing sales network in Zhejiang Province to purchase drugs from Tianshili Marketing Group for distribution and sales, thus expanding Jinhua Pharmaceutical Company's business scope, further enhancing the Company's market influence and enhancing the Company's marketing capability. At the same time, Tasly Marketing Group is an indirect holding subsidiary of the Company's associates, and the expansion of its sales channels has increased the scale of corporate sales. The connected transaction will not harm the interests of the Company or the minority shareholders.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 21, 2015
More information
In the eastern corner of the production area of Jianfeng Health Technology Company, there is a very inconspicuous building. From below, only a few pipes of uneven thickness can be seen on the top and the slogan "Focus on Environmental Protection and Promote Sustainable Development" with red letters on the yellow background on the stainless steel guardrail. Walking up, you can only see several closed pools and a small room with stacks of documents, test tubes, glass bottles and other testing tools on the table. This is the peak and healthy sewage treatment station. The production sewage of the whole factory area is concentrated here. After adjustment (PH adjustment), pre-acidification, anaerobic, anoxic, aerobic (aeration), precipitation and other links, it is discharged into the pipe network after reaching the special discharge standard. Yin Zhiwu, executive deputy general manager of Jianfeng Health, said that because the sewage treatment station in Wucheng District has not yet been built, Jianfeng Health has not yet been able to achieve pipe discharge, and the relevant national laws have strict requirements on the discharge of water pollutants from the extraction pharmaceutical industry. Sewage discharge must reach a special discharge limit, that is, chemical oxygen demand (COD) must be less than 50 mg/L. Enterprise development and environmental protection are both the concept of peak health since its establishment. In March this year, on the basis of the original environmental protection facilities, Jianfeng Health carried out technical renovation of waste gas collection and treatment facilities, and at the same time installed a sealing cover on the sewage treatment station to realize the closed collection of waste gas. Since the trial operation of this facility in mid-May, the overall effect has been obvious. The original treatment tank would emit an unpleasant smell during work, but now the smell has been significantly reduced. Compared with the young enterprise of peak health, the relatively "older" peak pharmaceutical has more experience in sewage treatment and environmental protection. Akihama
2020
07-31
2016 Annual General Meeting of Shareholders
News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)
2020
07-31
2016 Annual General Meeting of Shareholders
News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)
2020
07-31
2016 Annual General Meeting of Shareholders
News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)
2020
07-30
Jianfeng Pharmaceutical Won Advanced Collective of Municipal Red Cross Humanitarian Promotion Award
On April 24, the Red Cross Society of Jinhua issued a circular commending the advanced units and individuals of the 2016 Red Cross Humanitarian Promotion Award. Peak Pharmaceutical Company won the Red Cross Humanitarian Promotion Award for Advanced Collective. The Red Cross is a social relief organization engaged in humanitarian work, with the purpose of carrying forward the spirit of humanity, fraternity and dedication, protecting human life and health, and promoting the cause of peace and progress of mankind. As a socially responsible enterprise, Jianfeng Pharmaceutical has always attached importance to public welfare and charity work, vigorously promoted the spirit of the Red Cross, and vigorously supported the work of the Red Cross with practical actions. In September 2016, at the theme publicity activity of "World First Aid Day" and the opening ceremony of the municipal Red Cross emergency rescue station (point), Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, donated 6 AEDs known as "life-saving artifact" to the Red Cross on behalf of Jianfeng Pharmaceutical, it is equipped with six Red Cross emergency rescue service stations (points), namely, Jinhua high-speed railway station, sports center, cultural center, Shuanglong scenic spot, Siping village scenic spot and Suoyuan village scenic spot. The configuration of AED equipment has played a very good role in improving the emergency rescue capacity of Jinhua's key locations, and has been affirmed by the Red Cross and related units. (Spike Pharmaceuticals)
2020
07-31
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page